Arsenic Attenuates GLI Signaling, Increasing or Decreasing its Transcriptional Program in a Context-Dependent Manner

Bin Li, Camilla Giamberri, Bo Tang, Emily Winterbottom, Jun Long, Ke Jin, Zhiqiang Wang, Dennis Liang Fei, Dao M. Nguyen, Mohammad Athar, Baolin Wang, Pochi R. Subbarayana, Lily Wang, Priyamvada Rai, Bach Ardalan, Anthony J. Capobianco, and David J. Robbins

Molecular Oncology Program, Department of Surgery, Miller School of Medicine, University of Miami, Miami, Florida (B.L., C.G., E.W., J.L., K.J., Z.W., D.L.F., D.M.N., A.J.C., D.J.R.); General Surgery Center of PLA, Southwest Hospital, Third Military Medical University, Chongqing, China (B.T.); Sheila and David Fuente Graduate Program in Cancer Biology, Miller School of Medicine, University of Miami, Miami, Florida (J.L.); Program in Experimental and Molecular Medicine, Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire (D.L.F.); Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida (D.M.N., P.R.S., P.R., B.A., A.J.C., D.J.R.); Department of Dermatology, University of Alabama, Birmingham, Alabama (M.A.); Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York (B.W.); Division of Biostatistics, Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida (L.W.); Departments of Medicine (P.R.S., P.R., B.A.) and Biochemistry and Molecular Biology (A.J.C., D.J.R.), Miller School of Medicine, University of Miami, Miami, Florida; and Division of Geriatric Medicine and Palliative Care, Miller School of Medicine, University of Miami, Miami, Florida (P.R.)

Received July 14, 2015; accepted November 13, 2015

ABSTRACT

The metalloid arsenic is a worldwide environmental toxicant, exposure to which is associated with many adverse outcomes. Arsenic is also an effective therapeutic agent in certain disease settings. Arsenic was recently shown to regulate the activity of the Hedgehog (HH) signal transduction pathway, and this regulation of HH signaling was proposed to be responsible for a subset of arsenic’s biologic effects. Surprisingly, these separate reports proposed contradictory activities for arsenic, as either an agonist or antagonist of HH signaling. Here we provide in vitro and in vivo evidence that arsenic acts as a modulator of the activity of the HH effector protein glioma-associated oncogene family zinc finger (GLI), activating or inhibiting GLI activity in a context-dependent manner. This arsenic-induced modulation of HH signaling is observed in cultured cells, patients with colorectal cancer who have received arsenic-based therapy, and a mouse colorectal cancer xenograft model. Our results show that arsenic activates GLI signaling when the intrinsic GLI activity is low but inhibits signaling in the presence of high-level GLI activity. Furthermore, we show that this modulation occurs downstream of primary cilia, evidenced by experiments in suppressor of fused homolog (SUFU) deficient cells. Combining our findings with previous reports, we present an inclusive model in which arsenic plays dual roles in GLI signaling modulation: when GLIs are primarily in their repressor form, arsenic antagonizes their repression capacity, leading to low-level GLI activation, but when GLIs are primarily in their activator form, arsenic attenuates their activity.

Introduction

Arsenic is a widespread environmental toxicant that poses a significant threat to human health (Rahman et al., 2009). Chronic exposure to arsenic has been linked to increased risk of a variety of adverse human health outcomes, including cancer and developmental defects (National Research Council, 1999; International Agency for Research on Cancer, 2004). In contrast, formulations of arsenic have previously exhibited efficacy against a variety of human diseases, such as syphilis, agues, malaria, and leukemia (Au, 2011). Arsenic trioxide (ATO) is currently approved by the U.S. Food and Drug Administration for the treatment of acute promyelocytic leukemia (Mi, 2011). Despite the long history of human exposure to and usage of arsenic, the exact mechanisms by which arsenic exerts these biologic effects remain obscure.

The Hedgehog (HH) signaling pathway is one of the primary signal transduction pathways that govern the rapid growth and patterning of vertebrate embryos and regulate adult tissue homeostasis (Ingham and McMahon, 2001). Consistent with the important role that HH signaling plays during development and tissue homeostasis, deregulation of HH signaling leads to an array of developmental disorders and...
many types of cancer (Ruiz i Altaba, 2006; Jiang and Hui, 2008; Barakat et al., 2010). The HH family of ligands bind to their primary cellular receptor Patched1 (PTCH1) to initiate signaling (Robbins and Hebrok, 2007). Upon HH binding, PTCH1 releases its inhibitory effect on Smoothened (SMO), which subsequently triggers a series of cellular events that regulate the stability, proteolytic processing, and activity of the glioma-associated oncogene family zinc finger (GLI) family of transcription factors (GLI1–GLI3) (Robbins and Hebrok, 2007; Ruiz i Altaba et al., 2007). In the absence of HH, the full-length forms of GLI2 and GLI3 (GLI-FL) are processed into truncated repressor forms (GLI-R). In the presence of HH, this partial proteolysis is attenuated and instead GLI-FL is converted into its activated form (GLI-A). GLI trafficking through primary cilia is required for the conversion of GLI-FL to either its GLI-R or GLI-A forms (Robbins et al., 2012).

We previously suggested that HH pathway activation underlies the etiology of some arsenic-induced diseases (Fei et al., 2010). We showed that both short-term and chronic arsenic exposure activates HH signaling in primary cells, established cell lines, and certain tissues of exposed mice. We further showed that arsenic exposure levels are positively associated with HH pathway activity in human bladder cancer, a malignancy previously linked to chronic arsenic exposure (Fei et al., 2010). More recently, other reports have shown that arsenic inhibits HH signaling initiated by either HH treatment or high GLI levels, and researchers concluded that arsenic is a functional inhibitor of HH/GLI signaling (Kim et al., 2010, 2013; Robbins et al., 2012). GLI trafficking in accordance with protocols approved by the University of Miami Institutional Animal Care and Use Committee. HCT116 cells (2 × 10⁶) were injected subcutaneously onto the left flank area of 4- to 5-week-old female nude mice (Crl:NU-Foxn1(nu)). When the xenograft tumor reached a size of approximately 200 mm³, the mice were randomized into two groups and treated by intraperitoneal injection with vehicle (phosphate-buffered saline) or 10 mg/kg of ATO. After 2 days of treatment, the tumors and kidneys were harvested and RNA was extracted for qRT-PCR analysis.

Patient Samples. Details of the patient selection and treatment plan were previously described (ClinicalTrials.gov identifier NCT00449137) (Ardalan et al., 2010). Briefly, the enrolled patients harbored CRC at advanced metastatic stages and were refractory to at least two standard chemotherapy regimens including 5-fluorouracil. These patients were treated with ATO (0.15–0.20 mg/kg) for 2–10 treatment cycles, along with intermittent doses of 5-fluorouracil (Ardalan et al., 2010). Biopsies of CRC liver metastases and white blood cells (WBCs) were taken within 1 week before the start of ATO treatment, on day 23 of the first cycle, and after completion of the last treatment cycle in one patient (ID number 1). All fine-needle biopsies of CRC liver metastases were confirmed as malignant cells before further processing. Biopsies were stored in RNAlater (Ambion, Austin, TX) before total RNA isolation. WBCs were isolated as previously described (Subbarayan et al., 2002). Total RNA was isolated using TRizol (Invitrogen, Carlsbad, CA) and purified using RNeasy kits (Invitrogen), followed by gene expression analysis using qRT-PCR.

Statistical Analysis. Experiments were independently performed multiple times. Statistical significance was determined by the t test unless otherwise indicated. In all analyses, a P value < 0.05 was considered statistically significant.

Materials and Methods

Cell Culture, Reagents, and Assays. NIH-3T3 cells (American Type Culture Collection, Manassas, VA) and the colorectal cancer (CRC) cell lines SW480, DLD-1, and HCT116 (gifts from Dr. Ethan Lee, Vanderbilt University, Nashville, TN) were cultured as previously described (Li et al., 2014b). ATO (Trisenox; Cephalon, Frazer, PA) was used at the indicated concentrations or combined with recombinant HH (rHH C25II; R&D Systems, Minneapolis, MN) on cultured cells. RNA extraction, quantitative reverse-transcription polymerase chain reaction (qRT-PCR), luciferase reporter assays, and plasmids expressing MYC-tagged human GLI1 or GLI2 were previously described (Fei et al., 2010; Li et al., 2014a). MYC-tagged GLI3-R (expressing truncated GLI3, which lacks the GLI transcriptional activation domain) was a gift from Dr. Ariel Ruiz i Altaba (University of Geneva Medical School, Geneva, Switzerland).

Mouse Experiments. Animal experiments were conducted in accordance with protocols approved by the University of Miami Institutional Animal Care and Use Committee. HCT116 cells (2 × 10⁶) were injected subcutaneously onto the left flank area of 4- to 5-week-old female nude mice (Crl:NU-Foxn1(nu)). When the xenograft tumor reached a size of approximately 200 mm³, the mice were randomized into two groups and treated by intraperitoneal injection with vehicle (phosphate-buffered saline) or 10 mg/kg of ATO. After 2 days of treatment, the tumors and kidneys were harvested and RNA was extracted for qRT-PCR analysis.

Patient Samples. Details of the patient selection and treatment plan were previously described (ClinicalTrials.gov identifier NCT00449137) (Ardalan et al., 2010). Briefly, the enrolled patients harbored CRC at advanced metastatic stages and were refractory to at least two standard chemotherapy regimens including 5-fluorouracil. These patients were treated with ATO (0.15–0.20 mg/kg) for 2–10 treatment cycles, along with intermittent doses of 5-fluorouracil (Ardalan et al., 2010). Biopsies of CRC liver metastases and white blood cells (WBCs) were taken within 1 week before the start of ATO treatment, on day 23 of the first cycle, and after completion of the last treatment cycle in one patient (ID number 1). All fine-needle biopsies of CRC liver metastases were confirmed as malignant cells before further processing. Biopsies were stored in RNAlater (Ambion, Austin, TX) before total RNA isolation. WBCs were isolated as previously described (Subbarayan et al., 2002). Total RNA was isolated using TRizol (Invitrogen, Carlsbad, CA) and purified using RNeasy kits (Invitrogen), followed by gene expression analysis using qRT-PCR.

Statistical Analysis. Experiments were independently performed multiple times. Statistical significance was determined by the t test unless otherwise indicated. In all analyses, a P value < 0.05 was considered statistically significant.

Materials and Methods

Cell Culture, Reagents, and Assays. NIH-3T3 cells (American Type Culture Collection, Manassas, VA) and the colorectal cancer (CRC) cell lines SW480, DLD-1, and HCT116 (gifts from Dr. Ethan Lee, Vanderbilt University, Nashville, TN) were cultured as previously described (Li et al., 2014b). ATO (Trisenox; Cephalon, Frazer, PA) was used at the indicated concentrations or combined with recombinant HH (rHH C25II; R&D Systems, Minneapolis, MN) on cultured cells. RNA extraction, quantitative reverse-transcription polymerase chain reaction (qRT-PCR), luciferase reporter assays, and plasmids expressing MYC-tagged human GLI1 or GLI2 were previously described (Fei et al., 2010; Li et al., 2014a). MYC-tagged GLI3-R (expressing truncated GLI3, which lacks the GLI transcriptional activation domain) was a gift from Dr. Ariel Ruiz i Altaba (University of Geneva Medical School, Geneva, Switzerland).

Mouse Experiments. Animal experiments were conducted in accordance with protocols approved by the University of Miami Institutional Animal Care and Use Committee. HCT116 cells (2 × 10⁶) were injected subcutaneously onto the left flank area of 4- to 5-week-old female nude mice (Crl:NU-Foxn1(nu)). When the xenograft tumor reached a size of approximately 200 mm³, the mice were randomized into two groups and treated by intraperitoneal injection with vehicle (phosphate-buffered saline) or 10 mg/kg of ATO. After 2 days of treatment, the tumors and kidneys were harvested and RNA was extracted for qRT-PCR analysis.

Patient Samples. Details of the patient selection and treatment plan were previously described (ClinicalTrials.gov identifier NCT00449137) (Ardalan et al., 2010). Briefly, the enrolled patients harbored CRC at advanced metastatic stages and were refractory to at least two standard chemotherapy regimens including 5-fluorouracil. These patients were treated with ATO (0.15–0.20 mg/kg) for 2–10 treatment cycles, along with intermittent doses of 5-fluorouracil (Ardalan et al., 2010). Biopsies of CRC liver metastases and white blood cells (WBCs) were taken within 1 week before the start of ATO treatment, on day 23 of the first cycle, and after completion of the last treatment cycle in one patient (ID number 1). All fine-needle biopsies of CRC liver metastases were confirmed as malignant cells before further processing. Biopsies were stored in RNAlater (Ambion, Austin, TX) before total RNA isolation. WBCs were isolated as previously described (Subbarayan et al., 2002). Total RNA was isolated using TRizol (Invitrogen, Carlsbad, CA) and purified using RNeasy kits (Invitrogen), followed by gene expression analysis using qRT-PCR.

Statistical Analysis. Experiments were independently performed multiple times. Statistical significance was determined by the t test unless otherwise indicated. In all analyses, a P value < 0.05 was considered statistically significant.
Results

Because previous reports of arsenic’s effect on GLI/HH signaling have been contradictory (Fei et al., 2010; Kim et al., 2010, 2013; Beauchamp et al., 2011), we re-examined this question using experimental systems capable of showing both increases and decreases in GLI activity. Because ultimately our interest is in the effects of arsenic on human pathologies, we first examined the effects of ATO on GLI target genes in patient specimens obtained as part of an ATO clinical trial for CRC (Ardalan et al., 2010). Needle biopsies of CRC liver metastases, along with cognate nontumorigenic WBCs, were taken from these patients before, during, and after termination (in one patient) of ATO treatment. The expression of GLI target genes was subsequently examined in these primary tissue samples. For the patient from whom we had all three tissue samples (patient ID number 1), ATO attenuated GLI target gene expression and did so in a manner that was reversible upon ATO withdrawal (Fig. 1A). In contrast, ATO treatment activated GLI target genes in WBCs from this same patient (Fig. 1B). Notably, these effects on GLI signaling by ATO were also reversible upon ATO withdrawal (Fig. 1, A and B). When we extended this analysis to the five patients in our cohort for which we had such tissue samples (Fig. 1C), the expression of GLI/HH biomarkers was down-regulated in the majority of ATO-treated patient tumor samples (four of five patients for GLI1 and two of five patients for PTCH1), whereas PTCH1 was upregulated in WBCs in three of five patients. Although the small numbers of patient samples examined precludes a generalization of these results,
we were able to observe distinct modulation of GLI/HH signaling in tumors and WBCs within the same patient. This differential modulation of HH signaling in vivo occurred in response to therapeutically relevant doses of arsenic (Shen et al., 1997). Interestingly, GLI1 expression levels were higher in the tumor samples than in the matching WBC samples (Supplemental Fig. 1), consistent with previous reports showing higher levels of GLI activity in CRC metastases (Varnat et al., 2009).

Because we were unable to make statistically relevant conclusions regarding GLI modulation using our small cohort of arsenic-treated patients with CRC, we developed a CRC xenograft mouse model and examined the effect of ATO on GLI activity in the CRC and mouse tissue. HCT116 cells were used in this assay because this cell line, along with two other CRC cell lines, requires high levels of GLI activity (Varnat et al., 2009; Mazumdar et al., 2011a,b) for viability and is responsive to ATO in vitro (Fig. 2, A and B). HCT116 cells were implanted subcutaneously onto the flanks of immunocompromised nude mice. Once the tumors reached a size of approximately 200 mm³, mice were randomized to two treatment groups and were given daily doses of ATO (10 mg/kg) or vehicle for 2 days. Tumor tissues or mouse kidneys, which we previously showed to respond to arsenic by increasing GLI signaling (Fei et al., 2010), were harvested from these mice, and the expression of GLI1 and PTCH1 was determined by qRT-PCR. ATO treatment dramatically decreased the expression of GLI target genes in the CRC xenograft tumors (Fig. 2C). However, ATO also increased basal GLI activity in the kidneys of these same mice (Fig. 2D). Combined, these data suggest that ATO treatment can both decrease and increase GLI activity in the same experimental system, albeit in a tissue-dependent manner.

We hypothesized that ATO might modulate GLI activity in a manner dependent on the basal levels of GLI activity, which would be dictated by the GLI-R/GLI-A ratio (Ruiz i Altaba et al., 2007). To test this hypothesis, we examined the effects of ATO on GLI activity in NIH-3T3 fibroblasts, whose GLI signaling level can be modulated by HH ligands or SMO agonists (Fei et al., 2010; Kim et al., 2010). We treated NIH-3T3 cells with increasing doses of ATO in the absence of HH ligand and noted that ATO elevated the expression of GLI biomarkers (Fig. 3A, left), consistent with our previous report (Fei et al., 2010). However, when NIH-3T3 cells were treated with ATO in the presence of HH, which activates GLI-A but attenuates GLI-R activity, GLI1 and PTCH1 levels were attenuated in a dose-dependent manner (Fig. 3A, right). These results support the hypothesis that ATO can both activate and attenuate GLI signaling depending on its basal state; in this case, it does so in a single cell type. An alternative possibility is that cells with different GLI signaling levels may have differential rates of arsenic transport or methylation and thus production of arsenic metabolites, which may have distinct effects on GLI signaling. However, we tested the expression of the major arsenite transporters, AQP7 and AQP9, and arsenite methyltransferase, AS3MT, in wild-type (WT) mouse embryonic fibroblasts (MEFs) and did not find it to be significantly different (Supplemental Fig. 2) under conditions of low-level versus high-level GLI signaling.

We speculated that a unified mechanism to explain the seemingly conflicting effects of ATO on GLI activity might exist. One plausible hypothesis is that ATO targets the primary cilium, which is suggested to play dual roles in HH signaling (Han et al., 2009). Furthermore, one previous report indicated that ATO decreased the trafficking of GLI2 through primary cilia (Kim et al., 2010). We therefore tested the ability of ATO to attenuate HH signaling in MEFs lacking suppressor of fused homolog (SUFU), a pivotal negative regulator of HH
signaling, whose increased levels of GLI activity are activated independently of primary cilia (Zhang et al., 2009). ATO attenuated the constitutive GLI activity of SUFU−/−/−MEFs, but activated GLI activity in WT MEFs (Fig. 3B). Therefore, ATO can attenuate GLI activity downstream of SMO, independently of primary cilia, inconsistent with the hypothesis that ATO attenuates GLI-A by affecting its trafficking through the primary cilium.

We previously reported that the levels of GLI3-R were decreased in cells treated chronically with ATO (Fei et al., 2010), suggesting that the agonist effect of ATO may come from the degradation of GLI3-R protein. However, we found here that the agonist effect of ATO could be observed as early as 6 hours (Fig. 3C), before any detectable GLI3-R degradation (Fig. 3, D and E). To further explore the relationship between ATO exposure and GLI activity, we took advantage of immortalized GLI2−/−/−;GLI3−/−/−MEFs that lack the major repressor and activator GLI forms and consequently do not respond to HH (Lipinski et al., 2008). We transfected plasmids expressing GLI1 or GLI2, the major GLI-A forms, into these cells to activate GLI signaling. This exogenous GLI activity was subsequently attenuated by ATO (Fig. 4A). We next investigated the mechanism of GLI activation by ATO using WT and GLI2−/−;GLI3−/−/−MEFs, validating that ATO’s activation of GLI signaling requires GLI2 and/or GLI3 (Fig. 4B) (Fei et al., 2010). To further assess the effect of ATO on the dominant GLI-R (GLI3), we used GLI3−/−/−MEFs. In these cells, the loss of GLI3-R activity results in a net increase in basal GLI activity (Lipinski et al., 2008), driven by unpressed, basal GLI2 activity. Transfection of a plasmid expressing GLI3-R into these cells repressed PTCH1 expression to levels comparable with those of WT MEFs. ATO was capable of reversing this GLI3-R activity (Fig. 4C) and did so in a manner that did not decrease GLI3-R protein levels (Fig. 4D). This result is consistent with ATO acting directly to repress GLI3-R activity, with degradation of GLI3-R being a secondary effect of ATO subsequent to attenuation of its activity. Taken together, these results suggest that ATO is capable of attenuating both GLI-A and GLI-R activities, depending on which one is dominant in the cells.
Discussion

The mechanism and direction of modulation of GLI/HH signaling by arsenic has been controversial. We have previously shown, and also demonstrate here, that short and long-term exposure to arsenic activates GLI signaling. However, a number of other groups have argued that arsenic attenuates GLI signaling rather than activates it (Fei et al., 2010; Kim et al., 2010, 2013; Beauchamp et al., 2011; Han et al., 2013; Nakamura et al., 2013; Yang et al., 2013; You et al., 2014). We now show, in agreement with these previous groups, that arsenic can also antagonize GLI/HH signaling. Furthermore, we advance this work by showing that GLI activity can be activated or attenuated by arsenic in the same experimental systems, in vitro and in vivo. The disparate modulation of GLI activity we observe in these identical experimental systems is consistent with the modulation of GLI activity being context dependent, rather than resulting from experimental vagaries that can sometimes occur between different laboratories. Our NIH-3T3 data show that altering arsenic concentrations can both increase and decrease GLI signaling in a dose-dependent manner, depending on the presence or absence of HH. It is therefore unlikely that differential expression levels of arsenic transporters or arsenite methyltransferase is the primary mechanism responsible for the dual regulatory capacity of GLI/HH signaling by arsenic, at least in a single cell line. However, we cannot rule out that organic arsenic metabolites may be involved in the regulation of GLI activity by arsenic in more complicated systems such as human cancer patient samples, although inorganic arsenic has been reported to directly bind to GLI proteins (Beauchamp et al., 2011; Han et al., 2013), suggesting that inorganic arsenic is the main active arsenic species that modulates GLI activity.

Our results suggest that ATO acts as an unbiased GLI inhibitor, attenuating both its transcriptional activation and repressor activity. On the basis of results from a number of laboratories, including ours, we suggest that ATO attenuates GLI-A and GLI-R activity by binding directly to their zinc finger domains to disrupt their transcriptional regulatory functions. These effects occur downstream of primary cilia, on GLI proteins bound to the regulatory elements of their target genes. Alternatively, because arsenic has been implicated in global epigenetic modulation (Ren et al., 2011), ATO might regulate the activity of GLI target genes via epigenetic mechanisms. We do not favor this latter mechanism, because ATO is also capable of modulating the effects of exogenous GLI-A and GLI-R on a GLI-driven luciferase reporter gene, which should not be regulated by epigenetic mechanisms. We present here a unifying model to explain these cell context–specific responses to arsenic (Fig. 5). In cellular contexts with low GLI activity, GLI3-R plays a dominant role in repressing target gene transcription (Litingtung and Chiang, 2000; Pan et al., 2006) and ATO consequently binds to GLI3-R to attenuate this repression, which leads to increased GLI signaling. In cellular contexts harboring high GLI-A activity, ATO binds to GLI-A to attenuate GLI activity.

Acknowledgments

The authors thank the members of the Robbins’ laboratory and Drs. M. Karagas and E. Dmitrovsky for helpful discussions during the course of this study.

Fig. 5. A schematic model of how ATO modulates GLI/HH signaling in different contexts. ATO suppresses the activity of GLI proteins in both their activator and repressor forms. In cells with a low level of HH signaling, arsenic inhibits the repressor forms of GLI and thus results in a net increase in basal HH signaling (agonist mode). In cells with high levels of HH signaling, arsenic serves as an inhibitor of the activator forms of GLI (antagonist mode) and therefore decreases HH signaling.

Authorship Contributions

Participated in research design: Li, Giambelli, Tang, Winterbottom, Z. Wang, Fei, Nguyen, Athar, Subbarayan, Rai, Ardalan, Capobianco, Robbins.

Conducted experiments: Li, Giambelli, Tang, Winterbottom, Long, Jin, Fei, Subbarayan.

Contributed new reagents or analytical tools: Giambelli, B. Wang.

Performed data analysis: Li, Giambelli, L. Wang, Capobianco, Robbins.

Wrote or contributed to the writing of the manuscript: Li, Winterbottom, Subbarayan, Capobianco, Robbins.

References


**Address correspondence to:** Dr. David J. Robbins, Molecular Oncology Program, Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136. E-mail: drobbins@med.miami.edu